The E2F family of transcription factors play a key role in G1-S progression. A dominant negative mutant (E2F97) of E2F1 containing the DNA binding domain of E2F1 under the control of a tetracycline-responsive promoter was constructed. Stable transfectants were produced in the pRb-lacking SaOS-2 cell line and SV40-transformed VA-13 cell line, respectively. Induction of E2F97 by tetracycline withdrawal resulted in strong inhibition of the E2F transcriptional activity and a decreased percentage of cells in S-phase. To understand the mechanism(s) by which E2F97 exerts its eect on the cell cycle, the eect of E2F97 on expression of various cell cycle proteins was examined. Upon induction of E2F97, a signi®cant decrease in the levels of both dihydrofolate reductase and thymidylate synthase was observed in transfectants derived from both cell lines. Induction of E2F97 also led to a decrease in cyclin A and D1 protein levels. Regulation of cyclin A by E2F97 occurred at the transcriptional level. In addition, in VA13 cells, induction of E2F97 resulted in downregulation of the tumor suppressor protein p53. These data suggest that E2F regulates both G1 and S-phase cyclins and that there may be a potential positive feedback regulatory loop between E2F and cyclin D1.
Introduction
The cell cycle of mammalian cells is regulated by a very complex machinery, of which cyclins and cyclin dependent protein kinases (CDKs) play essential roles (Hatakeyama et al., 1994; Hinds et al., 1992; Peter and Herskowitz, 1994; Sherr, 1993; Hunter and Pines, 1994; Roberts et al., 1994; Pines, 1995; . Multiple cyclin-CDK complexes undergo changes in the kinase and cyclin moieties which are believed to drive the cell cycle from one stage to another. An important element of this cyclin regulated cell cycle is the rapid induction of cell cycle phase speci®c cyclin expression and facile destruction of these cyclins as cells progress through the next phase of the cell cycle. In mammalian cells, the D-type cyclins (reviewed in Peters, 1994; Sherr, 1995) , in association with the cyclin-dependent kinases cdk4 or cdk6, regulate the progression of the G 1 phase of the cell cycle mainly by participating in the phosphorylation of the retinoblastoma gene product pRb (Dowdy et al., 1993; Kato et al., 1993; Ewen et al., 1993; Weinberg, 1995) . As a result of phosphorylation of pRb, free E2F, of which ®ve members have been identi®ed to date (Xu et al., 1995; Sardet et al., 1995; Vairo et al., 1995; Hijmans et al., 1995; Buck et al., 1995) , is released from complexes containing E2F and the hypophosphorylated form of pRb. The`free' E2F, which is present as a heterodimer with its binding partner DP-1 or DP-2 (Wu et al., 1995; Zhang and Chellappan, 1995) , is the active transcription factor that promotes the transcription of E2F target genes such as dihydrofolate reductase (DHFR) (Slansky et al., 1993; Blake and Azizkhan, 1989) , thymidylate synthase (TS) (Johnson, 1994) , and other genes necessary for entry and progression through the S phase of the cell cycle (Adams and Kaelin Jr, 1995; Johnson et al., 1993; DeGregori et al., 1995) . More recent data suggest that the D-type cyclins may play a role in regulation of the activity of the pRb-like proteins p107 and p130 by a similar mechanism (i.e. phosphorylation of p107 or p130) (Suzuki-Takahashi et al., 1995; Beijersbergen et al., 1995; Mayol et al., 1995) . Other G1 cyclins (e.g. cyclins E and C) are also believed to play important roles in G1 progression and entry into S phase (Tassan et al., 1995; Ohtsubo et al., 1995; Duronio and O'Farrell, 1995) . Cyclin A and the B-type cyclins (cyclins B1 and B2), in complexes with CDK2 and CDC2, respectively, are essential for Sphase progression and for G 2 /M phase transition (Rosenblatt et al., 1992; Devoto et al., 1992; Pagano et al., 1992) .
The mammalian cell cycle is negatively regulated mostly through action of cyclin dependent kinase inhibitors (CDKIs) (reviewed in Grana and Reddy, 1995; Hirama and Koeer, 1995; Roberts et al., 1994; Sherr and Roberts, 1995) , many of which have been identi®ed recently (Toyoshima and Hunter, 1994; Guan et al., 1994; Chan et al., 1995; Serrano et al., 1993; Harper et al., 1993; Xiong et al., 1993; Lee et al., 1995) . Important CDKIs include p21 Waf1 , a universal CDK inhibitor (Xiong et al., 1993) whose expression is regulated by the p53 tumor suppressor protein (Waga et al., 1994; Li et al., 1994; Zhang et al., 1994) ; p16 INK4 , a speci®c inhibitor of cyclin D/CDK4/6 (Serrano et al., 1993) that is identi®ed recently as a tumor suppressor gene product (Marx, 1994) ; and p27 Kip1 , which is involved in cellular response to cAMP and other antiproliferative signals . p21
Waf1 plays a pivotal role in p53-mediated cell cycle arrest upon stress such as DNA damage (Brugarolas et al., 1995; Macleod et al., 1995) .
Although several cell cycle-related genes such as cdc2 and c-myc are known to be regulated by E2F (Oswald et al., 1994; North et al., 1996; Thalmeier et al., 1989) , other molecular targets of E2F are yet to be identi®ed. Previous work by other investigators showed that E2F may regulate thymidylate synthase (TS) (Johnson, 1994) , an enzyme critical for DNA replication, through a consensus E2F binding sequence located in the promoter region of TS. However, under in vivo conditions, the role of E2F in regulation of dihydrofolate reductase (DHFR), another enzyme involved in DNA synthesis, is not yet established although this enzyme also contains an E2F binding site in its promoter. E2F has been identi®ed as a down-stream target for the actions of the tumor suppressor proteins p53 and pRb. An increase in E2F transcriptional activity, as a consequence of loss of pRb function which negatively regulates E2F, is considered to be a critical factor in deregulation of the cell cycle and perhaps in tumorigenesis (Singh et al., 1994; Xu et al., 1995; Johnson et al., 1994) . In the current study we attempt to systematically identify the molecular targets and to understand the functional roles of E2F in cell cycle control. E2F overexpression has been used in most, if not all, of the previous studies for identifying the down-stream targets of E2F. The current study takes a more physiological approach, i.e., to use a dominant negative mutant of E2F (E2F97) (Dobrowolski et al., 1994) , which contains the DNA binding domain of E2F1 under the control of a tetracycline-responsive promoter. Stable transfectants were produced in the pRb-lacking SaOS-2 (human osteosarcoma) and SV40-transformed VA-13 (human ®broblast) cell lines, which were subsequently used as model systems to study the functional roles of E2F.
Results
Inducible expression of the dominant negative E2F mutant in Saos-2 and VA-13 cells and its eect on E2F transcriptional activity A human osteogenic sarcoma cell line (SaOS-2) and a human ®broblast line transformed with SV40 virus (VA-13) were transfected to obtain stable transfectants expressing an inducible dominant negative (DN) mutant of E2F under the control of a tetracycline (TC) responsive promoter. After G418 selection, clones from both cell lines were obtained which contained the DNA sequences of the dominant negative mutant of E2F, as shown by PCR analysis using a primer speci®c for the CMV promoter and another primer speci®c for the DNA sequence of the E2F mutant. Inducibility of the E2F mutant by the absence of tetracycline was veri®ed by measuring the inhibitory eect of the DN E2F mutant on the overall transcriptional activity of the endogenous E2F. The latter was measured by transient transfection of the PCR-positive stable transfectants with a reporter plasmid containing the E2F responsive promoter fused to a Chloramphenicol Acetyl Transferase (CAT) gene, followed by measurement of the CAT activity of the cell extract. As shown in Figure 1 , in either SAOS-2-E2F97 cells or VA13-E2F97 cells, there was a signi®cant reduction in the CAT activity (which was normalized with luciferase activity from the co-transfected pSV2luc) in cells grown in the absence of tetracycline as compared to cells grown in the presence of 1 mg/ml tetracycline. This dierence in CAT activity was not due to tetracycline because there was no dierence in CAT activity when either wild type SaOS-2 or VA-13 cells were transfected with the same reporter plasmid in the presence or absence of tetracycline (data not shown). These data indicated that inducible expression of the DN mutant of E2F markedly reduced the transcriptional activity of endogenous E2F in these cells and that expression of the DN mutant of E2F can be eectively controlled by tetracycline.
Eect of expression of the dominant negative E2F mutant on cell growth and cell cycle distribution Although induction of the DN E2F mutant in both SAOS-2-E2F97 and VA13-E2F97 cells had no eect on cell morphology, induction of the DN E2F mutant did lead to a somewhat slower cell growth (data not shown). The eect of the DN E2F mutant on cell cycle (i.e. % of cells in S-phase) was measured by pulsechase labeling of cells with bromodeoxyuridine (BrdU). BrdU-positive (i.e. S-phase) cells were quantitated by staining the labeled cells with a¯uorescein-conjugated monoclonal anti-BrdU antibody followed by¯ow cytometric analysis. As shown in Figure 2 , induction of the DN E2F mutant in SAOS-2-E2F97 cells led to a decreased percentage of cells in S-phase (i.e. from 26.8% to 11.7%). These data indicated that expression of the DN E2F mutant led to suppression of DNA synthesis and, as a result, inhibition of cells from entry into the S-phase of the cell cycle.
Eect of the dominant negative mutant of E2F on expression of certain S-phase enzymes Since induction of the DN E2F mutant in either SAOS-2-E2F97 or VA13-E2F97 cells inhibited entry of cells into S-phase of the cell cycle (Figure 2 ), Western blotting analysis was performed to determine whether the inhibition of S-phase entry is accompanied by decreased levels of dihydrofolate reductase (DHFR) and thymidylate synthase (TS), two S-phase enzymes that are essential for DNA replication and cell growth. When the DN E2F mutant was induced in SaOS-2- Figure 1 Eect of tetracycline on E2F transcriptional activity in Saos-2 and VA13 cells transfected with the dominant negative E2F mutant. Cells from a clone of Saos-2-E2F97 and a clone of VA13-E2F97 cells were plated in culture dishes in media containing or lacking tetracycline (2 mg/ml). After growth for 24 h, cells were co-transfected with pE2FCAT and pSV2luc. After an additional 72 h growth, the cells were collected and assayed for both CAT and luciferase activities. See the Materials and methods section for details. The results represent means+SE of the relative CAT activities (after correction for transfection eciency using luciferase activities) from three dierent experiments E2F97 cells by tetracycline withdrawal, there was a decrease in the levels of both DHFR and TS protein (compare lanes 1 and 2, Figure 3a) . Figure 3b and c show that in VA13-E2F97 cells, there was also a signi®cant reduction in the level of DHFR (3b) or TS (3c) upon induction of the DN E2F mutant. These results are consistent with previous observations (Johnson, 1994; Slansky et al., 1993; Blake and Azizkhan, 1989 ) that both TS and DHFR are regulated by E2F at the transcriptional levels, mediated by the E2F binding sites present in the promoters of TS and DHFR.
Eect of the dominant negative mutant of E2F on expression and kinase activity of cyclin A Although cyclin A, initially characterized as a`mitotic cyclin ' (Walker and Maller, 1991) , is considered to function as an S-phase cyclin (Zindy et al., 1992; Pagano et al., 1992) , recent work (Carbonaro-Hall et al., 1993; Rosenberg et al., 1995) suggests that cyclin A activity may also be essential for G 1 /S progression. Therefore, the eect of the DN E2F mutant on expression of cyclin A was studied. Western blotting using a speci®c antibody against cyclin A (Figure 4a ) indicated that induction of the DN E2F mutant by TC withdrawal in either SAOS-2-E2F97 cells (lanes 1 and 2) or VA13-E2F97 cells (lanes 3 and 4) led to a marked decrease in cyclin A protein. This suggests that E2F also positively regulates cyclin A, which is consistent with recent reports showing that E2F may regulate the promoter activity of cyclin A via a variant E2F binding site present within the promoter (Schulze et al., 1995) .
Cyclin A, like other cyclins, form active complexes with their corresponding CDKs (i.e. CDK2) to drive cell cycle progression (Devoto et al., 1992) . To determine whether downregulation of cyclin A by the DN E2F mutant plays a role in cell cycle regulation, cyclin A-associated kinase activity was determined by measuring the ability of the cyclin A immunoprecipitate from total cellular extract to phosphorylate Histone H1 protein. As shown in Figure 4b , when the DN E2F mutant was induced by TC withdrawal in SAOS-2-E2F97 cells, there was a signi®cant decrease in cyclin A-associated kinase activity compared to cells grown in the presence of TC. These data indicated that induction of the DN E2F mutant led to a decrease in cyclin A-associated kinase activity, consistent with the decreased level of expression.
Regulation of cyclin A by the dominant negative E2F mutant occurs at the transcriptional level
Transient transfection of SaOS-2-E2F97 cells with a plasmid containing the cyclin A promoter which drives the expression of the reporter gene luciferase was performed to measure the eect of induction of the DN E2F mutant on the promoter activity of cyclin A. As shown in Figure 5 , induction of the DN E2F mutant by TC withdrawal led to a signi®cant decrease in the Figure 2 Eect of dominant negative E2F mutant on the cell cycle. Cells from a clone of SaOS-2-E2F97 were plated in media containing or lacking tetracycline (2 mg/ml). After growth for 48 h, the cells were pulse chase labeled with BrdU and processed for ow cytometric analysis as described in the Materials and methods section. Relative FITC¯uorescence (vertical axis) was plotted as a function of DNA contents (PI¯uorescence, horizontal axis). Percent of cells in S phase (in the presence (C) or absence (B of TC) was calculated by use of a control (as a basis for estimating background¯uorescence (A) in which cells were processed in the same manner except that they were not labeled with BrdU. The results were representative of two independent experiments promoter activity of cyclin A (as indicated by relative luciferase activity after correction for transfection eciency using a separate reporter plasmid containing the CAT gene). These results indicated that the DN E2F mutant downregulates cyclin A expression, at least in part, at the transcriptional level.
Eect of the dominant negative mutant of E2F on expression of the D-type cyclins
The D-type cyclins, which are composed of three members (D1, D2, D3), are known to play essential roles in G 1 to S transition in the cell cycle (Sherr, 1995) , therefore it was of interest to determine whether the DN E2F mutant mediates cell cycle inhibition through regulation of any of the D-type cyclins. This was accomplished by Western blotting analysis, using available antibodies speci®c for two members of the Dcyclin family, cyclins D1 and D3, of protein extracts from SaOS-2-E2F97 and VA13-E2F97 cells grown in the presence or absence of TC. As shown in Figure 6a , when the DN E2F mutant was induced by TC withdrawal, there was a modest decrease in the level of cyclin D1 expression in both SAOS-2-E2F97 and VA13-E2F97 cells compared to the same cells grown in the presence of TC (compare lanes 1 and 2 and lanes 3 and 4). Induction of the DN E2F mutant did not cause a signi®cant change in the protein level of cyclin D3 (not shown). These data indicated that induction of the DN E2F mutant decreased expression of cyclin D1 but not cyclin D3.
The D-type cyclins, by forming complexes with CDK4 or CDK6, regulate the activities of these kinases, which are essential for G 1 progression. Therefore, it was necessary to determine whether the down-regulation of cyclin D1 by the DN E2F mutant is accompanied by decreased cyclin D1-associated kinase activities. As shown in Figure 6b , when the DN E2F mutant was induced by TC withdrawal in SAOS-2-E2F97 cells, there was a modest decrease in cyclin D1-associated kinase activity (using Histone H1 as the substrate) compared to the same cells grown in the presence of TC. This modest decrease in kinase activity is consistent with a relatively small (ca. two to threefold) decrease in cyclin D1 protein level induced by the DN E2F mutant (Figure 6a ). These data indicated that the down-regulation of cyclin D1 by the DN E2F mutant was accompanied by decreased cyclin D-associated kinase activity, which may contribute at least in part, to the inhibitory eect of the DN E2F mutant on G1-S transition (Figure 2) .
Eect of the dominant negative mutant of E2F on expression of cyclin E
It has been reported recently Ohtani et al., 1995) that cyclin E, an essential G1 cyclin, is positively regulated by E2F transcription factor(s). Therefore, the eect of induction of the DN E2F mutant on cyclin E expression was determined. As shown in Figure 7 , induction of the DN E2F mutant Cells from a clone of SaOS-2-E2F97 and a clone of VA13-E2F97 were plated in media containing or lacking tetracycline (2 mg/ml). After growth for 48 h, cells were collected and proteins (150 mg) from total cellular extracts were subjected to Western blotting analysis as described in the Materials and methods section. Cyclin A was visualized by use of a mouse monoclonal anti-cyclin A antibody. The position of cyclin A is indicated by the arrow. Shown is a representative of results obtained from two dierent experiments. (b) Eect of the dominant negative E2F mutant on cyclin A-associated kinase activity. Cells from a clone of SaOS-2-E2F97 (mid-log), maintained in the presence of TC, were grown to mid-log phase (a 48 h incubation) in media containing or lacking TC (2 mg/ml). Cells were collected and the total cellular extract (containing 200 mg protein) were subjected to immunoprecipitation with anticyclin A antibody-agarose conjugates followed by Histone H1 assay as described in the Materials and methods section. The position of the phosphorylated Histone H1 is indicated by the arrow. This represents one of two similar experiments by tetracycline withdrawal did not aect cyclin E expression in SaOS-2-E2F97 or VA-13-E2F97 cells (compare lanes 1 and 2 and lanes 3 and 4).
Eect of the dominant negative mutant of E2F on expression of p53
The tumor suppressor protein p53 is known to play essential roles in stress-induced cell cycle arrest and apoptosis. A recent report suggests that p53 is positively regulated by overexpression of E2F-1 in a myeloid cell line (32D.3) (Hiebert et al., 1995) . To con®rm this result and, more importantly, to determine whether E2F can regulate p53 expression under physiological conditions (i.e. without overexpressing E2F-1), the eect of the DN E2F mutant on p53 expression was studied in VA13-E2F97 cells (SaOS-2-E2F97 cells were not used due to the lack of p53 in this cell line). As shown in Figure 8 , when the DN E2F mutant was induced by TC withdrawal, there was a signi®cant decrease in the level of p53 expression. These data indicate that p53 is positively regulated by the E2F transcription factor under physiological conditions and that inhibition of E2F-transcriptional activity leads to down-regulation of p53.
Discussion
The current study takes advantages of a tetracycline inducible expression system stably integrated into cells Figure 5 Eect of the dominant negative E2F mutant on the transcriptional activity of the cyclin A promoter. Cells from a clone of SaOS-2-E2F97 (mid-log) were grown to ca 40 ± 50% con¯uency, in the presence or absence of TC. After 24 h growth, cells were co-transfected, using lipofection, with pAluc (which contains the cyclin A promoter driving the expression of the luciferase reporter gene) and pSV2CAT (which contains the CAT gene driven by the SV40 promoter) in the presence or absence of TC, respectively. After an additional 72 h growth, cells were collected and assayed for both CAT and luciferase activities as described in Materials and methods section. The results represent the means+SE of relative luciferase activities (after correction for transfection eciency using CAT activities) from three experiments
SaOS-2-E3F97 VA13-E2F97 a b Figure 6 (a) Eect of the dominant negative E2F mutant on expression of cyclin D1. Cells from a clone of SaOS-2-E2F97 and a clone of VA13-E2F97 were plated in media containing or lacking tetracycline (2 mg/ml). After growth for 48 h, cells (midlog phase) were collected and proteins (150 mg) from total cellular extracts were subjected to Western blotting analysis as described in the Materials and methods section. Cyclins D1 (a) was visualized by use of a mouse monoclonal anti-cyclin D1 antibody. The position of cyclins D1 is indicated by the arrow. Shown is representative of results obtained from three dierent experiments. (b) Eect of the dominant negative E2F mutant on the D-type cyclin-associated kinase activity. Cells from a clone of SaOS-2-E2F97 (mid-log), maintained in the presence of TC, were grown to mid-log phase (after a 48 h incubation) in media containing or lacking TC (2 mg/ml). Cells were collected and the total cellular extract (containing 200 mg protein) were subjected to immunoprecipitation with anti-cyclin D1 antibody followed by Histone H1 assays as described in Materials and methods section. The position of the phosphorylated Histone H1 is indicated by the arrow. One of two similar experiments is shown
SaOS-2-E3F97 VA13-E2F97 Figure 7 Eect of the dominant negative E2F mutant on expression of cyclin E. Cells (mid-log) from a clone of SaOS-2-E2F97 and a clone of VA13-E2F97 were plated in media containing or lacking tetracycline (2 mg/ml). After growth for 48 h, cells were collected and proteins (150 mg) from total cellular extracts were subjected to Western blotting analysis as described in the Materials and methods section. Cyclin E was visualized by use of a mouse monoclonal anti-cyclin E antibody. The position of cyclin E is indicated by the arrow. Shown is a representative of results obtained from two dierent experiments
Figure 8 Eect of the dominant negative E2F mutant on expression of p53. Cells (mid-log) from a clone of VA13-E2F97 were plated in media containing or lacking tetracycline (2 mg/ml). After growth for 48 h, cells were collected and proteins (150 mg) from total cellular extracts were subjected to Western blotting analysis as described in the Materials and methods section. The p53 protein was visualized by use of a mouse monoclonal antip53 antibody. The position of p53 is indicated by the arrow. Shown is a representative of results obtained from three independent experiments and a perhaps more physiological approach (i.e. the use of a dominant negative mutant of E2F) to study the functional roles of E2F in relationship to cell cycle regulation. This dominant negative E2F mutant, which encodes the DNA binding domain of E2F-1, was shown previously (Dobrowolski et al., 1994) to be a potent (almost stoichiometric) and speci®c inhibitor for E2F-1-and E1A-induced DNA synthesis. The notion that overexpression of E2F is oncogenic (Singh et al., 1994; Xu et al., 1995; Johnson et al., 1994) and that E2F is a potential therapeutic target (Morishita et al., 1995) prompted us to choose cell lines having elevated levels of`free' E2F to study the functional consequences of the inhibition of such elevated E2F activity. For this reason, two cell lines (SaOS-2 and VA13) were chosen as the experimental models in the current study, which, as a result of the lack of functional pRb and p53 (due to either deletion (SaOS-2 cells) or inactivation by the large T antigen of the SV40 virus (VA13)), have elevated levels of`free' E2F (Fan and Bertino, unpubilshed data) (Li et al., 1995) . The latter (VA13) cell line is the SV40 virus-transformed derivative of a human diploid ®broblast (WI-38) cell line. Since loss of both functional pRb and p53 is common in tumors from cancer patients, the results obtained from the current study may have direct therapeutic implications. The DN E2F mutant used in the current study is a competitive inhibitor of endogenous E2F for binding to the E2F binding sites present in the promoters of various genes. Although the DN E2F mutant lacks the binding site for DP-1 or -2, the binding partners of E2Fs, which seem to be necessary to form E2F/DP heterodimers for strong binding to the E2F recognition sequences (Helin et al., 1993) , our current work suggests that this DN E2F mutant was capable of competing with endogenous E2F (most likely present as a heterodimer with DP-1 or -2) for binding to DNA and, as a result, inhibiting the transcriptional activity of E2F. This result is consistent with ®ndings from a previous study that a similar DN E2F mutant (also lacking the DP binding site) in the form of a GSTfusion protein was capable of competing on equal molar basis with full length E2F-1 for binding to the E2F recognition sequence-containing oligonucleotide (Dobrowolski et al., 1994) . Since all ®ve members of the E2F family (E2F1-5) are able to recognize the same consensus DNA binding-sequence , it is likely that the DN E2F mutant, in spite of being derived from E2F-1, is inhibitory to all E2F family members. Whether the degree of inhibition by the E2F mutant varies among individual E2F family members remains to be investigated.
Several reports (Weinberg, 1996; Zwicker et al., 1996; Sellers et al., 1995) suggest that Rb-E2F complexes, rather than representing`inactivated' or sequestered' E2F, actively repress transcription in a DNA-binding-dependent manner. The data presented in this paper, along with those by other investigators (Dobrowolski et al., 1994; Morishita et al., 1995) , however, suggest that prevention of E2F from binding to its DNA recognition sequences may be sucient, at least in some instances, to exert a negative eect on the cell cycle and cell cycle related gene expression. Morishita et al., using a similar strategy to the one presented in this paper demonstrated that expression of a transcription factor decoy of the consensus E2F binding site inhibited smooth muscle proliferation both in vitro and in vivo (Morishita et al., 1995) .
Two recent reports (Field et al., 1996; Yamasaki et al., 1996) showed surprisingly that`knockout' mice lacking E2F-1 displayed either tumor induction and tissue atrophy or a defect in T lymphocyte development (due to a defect in thymocyte apoptosis) and suppression of cell proliferation. From these ®ndings, it was suggested by Weinberg (Weinberg, 1996) that E2F-1 may be both an oncogene and a tumor suppressor gene. These ®ndings, however, neither approve nor disapprove the plausibility of E2F being a good therapeutic target because there are several fundamental dierences between these E2F-1 knockout studies and the current study. First, E2F-1 knockout' is not equivalent to inhibition of E2F transcriptional activity (e.g. via expression of a dominant negative inhibitor such as the one used in this paper) since it is possible that E2Fs may have functions (including a`tumor suppressor' function which may not necessarily be related to the transcriptional activity of E2F) in addition to serving as transcription factors. For example, use of dominant negative mutant of E2F may keep the tumor suppressor function intact while the E2F knockout will completely destroy this function, leading to formation of tumors. Secondly, formation of tumors as a result of E2F-1 de®ciency may not be necessarily directly caused by loss of E2F-1 function since other events such as developmental defects may be involved in tumor development. Thirdly, it is yet to be proved that knocking out multiple E2F family members will generate the same phenotype (i.e. formation of tumors) as E2F-1 knockout. Fourthly, there may be a fundamental dierence between inhibition of E2F activity in tumors and in normal tissues. Normal tissues may require E2F-1 function for normal development (therefore lack of E2F-1 may cause developmental defects and, as a result, possibly tumor formation) while tumor cells may depend on E2F activity for outgrowth. Therefore, it is possible that inhibition of E2F in tumor cells will have only one consequence, i.e. suppression of tumor growth. This is true especially if the tumors lack functional p53 (due to either mutation/deletion or inactivation by viral oncoproteins), which occurs in the majority of tumors (Levine et al., 1991; Hollstein et al., 1991) . Interestingly it was observed in the current study that some (ca. 50%) of the PCR-positive clones of E2F97 transfectants of SaOS-2 and VA-13 cells showed slower growth rate and eventually died when cultured for long periods in TC-lacking media (data not shown), indicating that inhibition of E2F activity may be detrimental to some tumor cells.
The observation that p53, an apoptosis and negative cell cycle regulator, is down-regulated by the DN E2F mutant suggests that E2F may also negatively regulate the cell cycle by inducing p53. A previous study (Hiebert et al., 1995) suggested that E2F enhances apoptosis by induction of p53. It will be interesting to examine the possibility that regulation of p53 by E2F plays a role in the tumor formation in the E2F-1 knockout mice vide supra, raising the possibility that E2F may be a tumor suppressor regulator rather than a tumor suppressor itself.
The inhibitory eect of the DN E2F mutant on the cell cycle, measured by use of pulse chase labeling of cells with BrdU, suggests that the DN E2F mutant is capable of inhibiting DNA synthesis, and as a result, entry of cells into the S-phase. Interestingly, when cells were labeled with only propidium iodide (PI) (a DNA content indicator), there were no major dierences between the overall cell cycle distribution (i.e. % of cells in S, G 1 or G 2 /M phase) between cells grown in the presence of TC and those in the absence of TC (data not shown). One possible explanation for this discrepancy would be that the DN E2F mutant may have exerted roughly equal inhibitory eect on each phase of the cell cycle so that the cell cycle distribution of an unsynchronized cell population at any given time is not changed although the overall cell cycle may have lengthened, as indicated by a slower cell growth rate upon induction of the DN E2F mutant. A similar disagreement between cell cycle distribution (no change) and DNA synthesis (inhibited) was reported previously (Lowkvist et al., 1986) .
Data presented in this paper suggest that there may be a possible feedback regulatory loop between E2F and cyclin D1. Regulation of cyclin D1 by E2F is consistent with the fact that the promoter of cyclin D1 contains a consensus E2F binding site (Herber et al., 1994) . This regulatory loop becomes more important when cells lack functional pRb, which has been shown previously to positively regulate cyclin D1 . In the absence of pRb, the D-type cyclins may regulate the cell cycle progression by acting on the pRb-related proteins p107 and p130 (Suzuki-Takahashi et al., 1995; Beijersbergen et al., 1995; Mayol et al., 1995) . For unclear reasons, a previously observed autoregulatory loop between E2F and cyclin E (Geng et al., 1996; Ohtani et al., 1995) was not evident in the current study, perhaps due to dierent cell lines used.
Data presented in this paper also suggest that E2F may modulate the cell cycle by regulating both G1 and S-phase cyclins. Since cyclin A is also considered to be a mitotic cyclin (Walker and Maller, 1991) , E2F may also regulate G 2 /M phase of the cell cycle, thereby making E2F an`universal' cell cycle regulator.
The DN E2F mutant used in the current study has been shown to be a true E2F reagent (antagonist) in the context of the functional roles of E2F in cell cycle regulation and may be valuable for identifying other E2F target genes.
Materials and methods

Chemicals and reagents
Tetracycline, bromodeoxyuridine (BrdU), propidium iodide, histone H1, bovine serum albumin (BSA), and acetyl CoA were obtained from Sigma. Geneticin (G418) was obtained from Life Technologies (Gaithersburg, MD).
[g-32 P]-ATP (6000 Ci/mmole), Econo¯uor-2, and [acetyl-1-14 C]-acetyl Coenzyme A were purchased from Dupont NEN. Media and sera for cell culture were purchased from Grand Island Biological Co, Grand Island, NY. Protein A/ Protein G Plus Agarose was obtained from Oncogene Science. Liposomes (DOTAP/DOPE) used for transient transfections (see below) were either purchased from Boehringer Mannheim (Indianapolis, IN) or made available by the Liposome Facility, Department of Medicine, Cornell University Medical College, NY. All other chemicals were reagent grade and from standard commercial sources.
Antibodies
Antibodies against K-ras, cyclin D1, cyclin D3, cyclin A, cyclin E, p53, and anti-cyclin A-agarose conjugates were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). FITC-conjugated Anti-BrdU antibody was purchased from Becton Dickinson Immunocytometry Systems (Mountain View, CA). Polyclonal antibodies against human dihydrofolate reductase (DHFR) and thymidylate synthase (TS) were generous gifts from Dr Bruce Dolnick and Dr Frank Maley, respectively.
Cell lines
The SaOS-2 and VA-13 cell lines were obtained from American Type Culture Collection and were maintained as monolayer cultures at 378C in a 5% CO 2 /95% air incubator in RPMI 1640 medium supplemented with 10% fetal bovine serum.
Plasmids
The tetracycline inducible system plasmids pUHD10-3 and pUHD15-1 (Gossen and Bujard, 1992) were generous gifts from Dr Herman Bujard (Heidelberg, Germany). pAluc, which contains the cyclin A promoter linked to the ®re¯y luciferase cDNA (Henglein et al., 1994) , was provided by Dr Berthold Henglein (Paris, France). pE2FCAT which contains the E2F-responsive promoter linked to the Chloramphenicol Acetyl Transferase (CAT) cDNA (Buck et al., 1995) was provided by Dr ReneÂ Bernards (Amsterdam, The Netherlands). All plasmid DNAs were prepared from E. coli strain DH5a and puri®ed by ion exchange chromatography using the Plasmid Midi Kit from Qiagen (Chatsworth, CA).
Construction of an inducible vector system for the dominant negative mutant of E2F1
The tetracycline responsive system (Gossen and Bujard, 1992) , which is composed of two plasmids (pUHD10-3 and pUHD15-1), was used to construct the inducible vectors for controlled expression of the E2F1 mutant. First, pUHD15-1 was modi®ed to contain the selectable marker neo. This was accomplished by cloning the 1.1 kb tTA fragment from pUHD15-1 into the multiple cloning site of the plasmid pcDNA3 (Invitrogene, CA); the resulting plasmid is designated as pcdtTA. Then pUHD10-3 was modi®ed to contain the cDNA sequences for the E2F-1 mutant (E2F97), which encodes the DNA binding domain of E2F-1 (amino acids 95-191) (Dobrowolski et al., 1994; Helin et al., 1993) ; The latter was obtained by Polymerase Chain Reaction (PCR) using appropriate primers. The resulting plasmid is designated as pUHDE2F97.
Stable transfection of the E2F mutant expression system into cell lines
The transfection of cell lines (SaOS-2, a human osteosarcoma cell line and VA-13, an SV40 transformed human ®broblast cell line) with the tetracycline responsive system was accomplished by use of a two plasmid co-transfection protocol and a lipofection procedure (Stamatatos et al., 1988) . Cells were allowed to grow to ca. 50% con¯uency in a 100 mm Petri dish in a medium containing 1 mg/ml tetracycline. A total of 20 mg of the two plasmids (pUHDE2F97 and pcdtTA) at a molar ratio of 10 : 5 were mixed with 70 ml of the lipofectant DOTAP (Boehringer Mannheim) in a total of 0.5 ml HBS (20 mM HEPES, pH 7.4, and 150 mM NaCl) and incubated at room temperature for 10 min. Fourteen ml of fresh growth medium containing tetracycline were added and, after removal of old medium from cells, the mixture was then added to cells and incubation continued for 24 h. Cells were split 1 : 5 and grown in a medium containing 1 mg/ml tetracycline. G418 selection began 24 h later at a concentration just high enough to kill 100% of the parental (untransfected) cells. About 2 ± 5 weeks later, colonies were picked by cloning cylinder techniques and expanded into cell lines.
Western blot analysis
SaOS-2-E2F97 or VA13-E2F97 cells were grown to midlog phase in the presence of 2 mg/ml of TC. After being washed extensively to remove extraneous TC, the cells were collected by trypsinization and split equally into two culture¯asks containing or lacking 2 mg/ml TC, respectively. After 24 h incubation, the medium in each¯ask was changed with fresh media containing or lacking 2 mg/ml TC. After an additional 48 h incubation, cells were harvested by trypsinization, washed with Phosphatebuered Saline (PBS), and solubilized with a buer (50 mM NaCl, 20 mM Tris-HCl, pH 7.4) containing 2% (v/v) Nonidet P-40 (NP-40), 0.5% (w/v) sodium deoxycholate, and 0.2% (w/v) sodium dodecyl sulfate, plus a mixture of protease inhibitors (20 mg/ml leupeptin, 30 mg/ ml aprotinin, 10 mg/ml pepstatin A, 20 mg/ml soybean trypsin inhibitor, 1 mM phenylmethylsulfonyl¯uoride (PMSF), and 1 mM sodium orthovanadate). The extract was centrifuged at 60 000 g for 30 min to remove any insoluble cellular debris and the protein concentration was determined by the BCA assay according to the manufacturer's instructions (Pierce). The cell extract (containing 150 mg of total protein) was mixed with equal volume of 26 Sodium dodecyl sulfate (SDS) sample buer (20% (v/ v) glycerol, 125 mM Tris-HCl, pH 6.8, 4% (w/v) SDS, 1% (v/v) b-mercaptoethanol and 0.05% (w/v) bromophenol blue) and loaded onto a 12.5% polyacrylamide gel containing SDS (Laemmli, 1970) . After electrophoresis, the proteins were electro-transferred to a nitrocellulose membrane and the latter was probed with an antibody (either a mouse monoclonal or a rabbit polyclonal), followed by a second antibody (either anti-mouse IgG or anti rabbit IgG) conjugated with peroxidase. The protein of interest was then visualized by treatment of the membrane with the Enhanced Chemiluminescence (ECL) reagents (Amersham) followed by exposure to a X-ray ®lm.
Cell cycle analysis
Cells (5 ± 10610 6 ) growing exponentially at ca. 70% con¯uency in the presence or absence of TC (2 mg/ml) were pulse-chase labeled with 10 mM BrdU for 3 h at 378C in a CO 2 incubator. Cells were washed twice with PBS/BSA (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na 2 HPO 4 , 1.4 mM KH 2 PO 4 , and 1% (w/v) BSA) and detached from the¯ask by trypsinization. After centrifugation at 5006g for 15 min at 48C and resuspension in 100 ml of normal saline (0.9% (w/v) NaCl) on ice, the cells were slowly added drop-wise to 5 ml pre-chilled (7208C) 70% ethanol while maintaining a vortex. After incubation on ice for 30 min, the cell pellet was obtained by centrifugation, washed once with cold PBS, and resuspended by vortexing in 1 ml of 2N HCl containing 0.5% (v/v) Triton X-100. After another incubation for 30 min at room temperature, the cells were centrifuged at 5006g for 10 min and the pellet was resuspended in 1 ml of 0.1 M Na 2 B 4 O 7 (pH 8.5). Cells (1610 6 ) were centrifuged and the pellet was resuspended in 50 ml PBS containing 0.5% (v/v) Tween-20 and 1% (w/v) BSA. After addition of 20 ml of¯uorescein isothiocyanate (FITC)-conjugated anti-BrdU antibody and incubation for 30 min at room temperature, the cells were pelleted by centrifugation and resuspended in 1 ml PBS containing 5 mg/ml of propidium iodide (PI). The cell suspension was stored at 48C overnight before analysis with a Becton Dickinson FACS¯ow cytometer. BrdU staining (FITC uorescence) was plotted as a function of DNA content (PĪ uorescence). Cells which were not labeled with BrdU but stained with FITC-BrdU antibody served as the control for background or non-speci®c anti-BrdU¯uorescence so that percent of BrdU-positive (i.e. S-phase) cells could be calculated.
Histone H1 kinase assays
The following was based on the procedures of Bortner and Rosenberg (Bortner and Rosenberg, 1995) , with modifications. Cells (1610 7 ) growing exponentially at ca. 70% con¯uency in the presence or absence of TC (1 mg/ml) were collected and the cell pellet was resuspended in 0.2 ml lysis buer (100 mM Tris-HCl (pH 7.5) containing 300 mM NaCl, 2% (v/v) NP-40, 0.5% sodium deoxycholate, 0.2% (w/v) SDS, 20 mg/ml leupeptin, 30 mg/ml aprotinin, 10 mg/ ml pepstatin A, 20 mg/ml soybean trypsin inhibitor, 1 mM PMSF, and 1 mM sodium orthovanadate). After incubation for 30 min on ice, the cell lysate was centrifuged at 15 000 r.p.m. (Eppendorf) for 15 min at 48C. The protein concentration of the supernatant was determined by the BCA assay as described above. The cell extract containing 200 mg of protein was treated with 50 ml of protein A/ protein G plus agarose on a rotator for 30 min at 48C and the agarose beads were pelleted by centrifugation for 5 min at 15006g (Eppendorf). The supernatant was then mixed with 16 ml of anti-cyclin A-agarose or with 3 mg of anticyclin D1 antibody plus 50 ml protein A/protein G plus agarose. The mixture was rotated at 48C for 16 h and the agarose beads were recovered by centrifugation, washed 46 with lysis buer, and once with kinase buer (50 mM HEPES (pH 7.5) containing 150 mM NaCl, 10 mM MgCl 2 , 1 mM dithiothreitol (DTT) and 2 mM ethylene glycosyl-bis(b-aminoethyl ether) N,N,N',N'-tetraacetic acid (EGTA)), and resuspended in 20 ml (for cyclin A) or 30 ml (for cyclin D1) of kinase buer containing 100 mg/ml Histone H1, 10 mM ATP and 300 mCi/ml [g-32 P]-ATP. The kinase reaction was allowed to proceed for 1 h at 308C and was stopped by addition of equal volume of 26SDS sample buer (see above). After being boiled for 3 min, the mixture was loaded onto a 12.5% polyacrylamide gel containing SDS and electrophoresis was performed at 10 mA at 48C until the dye front reached 2 cm from the bottom of the gel. The gel was then dried and exposed to an X-ray ®lm.
Transient transfections
SaOS-2-E2F97 or VA13-E2F97 cells were grown to midlog phase in the presence of 2 mg/ml of TC. After being washed extensively to remove extraneous TC, the cells were collected by trypsinization and seeded at 1610 6 cells per plate into two separate sets of 100 cm culture dishes both of which contain 10 ml of RPMI 1640 medium supplemented with 10% serum; one group had 1 mg/ml of TC added and the other had no TC. After 24 h incubation at 378C, the medium in each set of dishes was changed with fresh respective media containing or lacking 1 mg/ml TC and incubation continued for 5 h. Ten mg of total plasmid DNA consisting of the reporter plasmid and control plasmid were mixed with 0.5 ml serum-free RPMI 1640 medium and the resulting DNA mixture was incubated for 1 h at room temperature. Fifty mg of the lipofectant DOTAP/DOPE (1 : 1) were mixed with 0.5 ml serum-free RPMI 1640 medium and the resulting liposome mixture was incubated for 1 h at room temperature. The DNA mixture and the liposome mixture were combined and incubated for another 30 min at room temperature. The DNA/liposome mixture, after being diluted by addition of 6.5 ml of RPMI 1640 medium supplemented with 0.1% serum, with or without 1 mg/ml of TC, was added to cells in the culture plates (see above) whose medium had been removed. After incubation at 378C for 5 h, 7.5 ml of RPMI 1640 medium supplemented with 20% serum, with or without TC, was added to each dish and incubation was continued at 378C for 16 h. Medium from each dish was replaced with fresh medium supplemented with 10% serum, with or without 1 mg/ml of TC, respectively and incubation was continued further at 378C for 48 h. After being washed twice with PBS, the transfected cells from each dish were recovered by use of 0.6 ml of the Reporter Lysis Buer (Promega) and by scraping with a rubber policeman. The cell lysate was transferred to an Eppendorf tube and centrifuged to pellet large cell debris. The supernant was stored at 7708C or used immediately for CAT and luciferase assays (see below).
CAT and luciferase activity assays
The CAT activity of the cell lysate prepared from the transfected cells (see above) was measured by use of 14 Clabeled acetyl Coenzyme A and chloramphenicol as substrates and a radio diusion procedure according to manufacturer's instructions. Brie¯y, 50 ml of cell lysate was mixed with 0.2 ml 1.25 mM Chloramphenicol in 100 mM Tris buer (pH 7.8) in a 7 ml glass scintillation vial. The reaction was initiated by adding 0.1 mCi [ 14 C] Acetyl CoA and 22.5 ml 1 mM cold acetyl CoA. Five ml of Econ¯uor-2 was gently overlaid and the vials were incubated at room temperature. At time intervals, the vials were counted using a Beckman Liquid Scintillation Counter. Relative CAT activity was calculated by comparison of the increase in counts over time. The luciferase activity was measured by use of the Luciferase Assay Reagent (Promega) according to the manufacturer's instructions. Brie¯y, 20 ml of cell lysate and 100 ml of the Luciferase Assay Reagent, both of which were pre-warmed to room temperature, were mixed and the relative light units produced for a period of 20 s were measured immediately on a luminometer.
